CA2345482A1 - Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby - Google Patents
Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby Download PDFInfo
- Publication number
- CA2345482A1 CA2345482A1 CA002345482A CA2345482A CA2345482A1 CA 2345482 A1 CA2345482 A1 CA 2345482A1 CA 002345482 A CA002345482 A CA 002345482A CA 2345482 A CA2345482 A CA 2345482A CA 2345482 A1 CA2345482 A1 CA 2345482A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- treatment
- paclitaxel
- albumin
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Use of microparticles of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors sensitive to Paclitaxel, and the drug obtained thereby.
Description
Lti/U4 U1 ~lli 14: uo !~~ ++.!b UL Lt~a~.~4o.>1 llVl..l.lA~eittUl.mm_. ~,~.~~.
USE OF PACLTTAXEL STABILIZED WITH AhBUMIN FOR PR»PARIN(~ A
DRUG FOR THE TRI~ATl'4~1~IT Ulr' SOLID TUMORS AND THE DRUG
OBTAINED Z'IiEREBY
The invention rclat~~s~ to a drug for the treatment of Paclitaxel, and the use of albumin micropart~:cles incorporatirlg~ Paclitaxel (and lutown by the name of ADI 007) in the prcpttration of this drug.
Paclitaxel is a sttbstanr_e well known in the literature, with important clinical activity on a large number of tumors, such as ovary, Iung, head and t 0 neck, bladder and breast tumors.
Paclitaxel is insoluble in water. Irt order to render it soluble and suitable for intravenous ad~m.fnistration, it has been mixed with a surfactant (such as isolyethoxylatcd castor oil, lmoan~ by the registered name "CLCr.11up11u1 EL") and with about 50% of ranhydrous alcohol USP, ae vehicles for the 5 ParlitaxPl: thi4 mixture was patented by tiristoi-Myers Squibb and tg known by Llle, 1'C~,l'.fLClCl1 Liaiut "Taxol" to which ccfcrcnce will be tuadc hereiliaft~r, for oimplieity. The pre: once of the Surfactant and the anhydrous alcohol has CPT1f117S drawhar:kq, g»c:h as strong hypersensitivity, in addition to other side effects.
20 fn tiny ever~t,. Taxol is admixiiatered, and can be administered, only by isltravenous injection, with carry Ir_.zt,gthy admtnxgtra.tinn timrc tt~
Qxt attem.rt to minimize the toxic effects of ithe product.
To overoonne the aforesaid drawbar.L~s, the said Bristol-Myers Squibb has patented (European Parent Arrli~atinns FP..A-()Sii4()()l, H;P-A-()7lialili5, W EP-A-0783886 and United SldlCS Pr~lCIlls US 5641803 a.cld U3 5670537) ovrnpositiona also containing, in addition to Texol, other oub3tEtrtce3 or medicaments able to impedC SG:r1011S a~.Rj~h3rlR~xi~ rPa~tiflnC.
According LO the laiown arl.. its drsc,-ribcd W tile d!'urcad.iQ pGtLC~lts, from l;ib to 1'75 trig of Taxol per m2 of the patient's body surface are 30 adrninistercd intravenously to petticnt3 3ubjeeted to therapy, each adsxximistration being effected very slowly, over a dttratiori of Ahntlt 3 hnmrw it is essential always to use the aforementioned medicaments.
U3 5439686, US 5498421 and US 55609$3 deocribe albumin_ microparticles incorporating th~P Pa~litax~:l: thPSp particles are internationally identified by the symbols ABI OC17, this denomination being used hereinafter for simplicity whenever reference is made to these microparticles.
ABI 007 is in practice a formulation of Paclitaxel stabilized by human albumin USP, which care be dispersed in physiological solution which is directly injectable, being free of 'toxic emulsifiers.
It has been surprisingly found that ABI 700 can be used to prepare drugs in which the ABI 007 is present as a dispersion in physiological solutions at a concentration between 2 rng and 8 mg per ml of these solutions, and that this drug can be injected directly into those arteries which feed the terntory associated with a tumor sensitive to Paclitaxel, with administrations effected over durations much shorter than are possible in the known art, and repeated just a few times.
Compared with the teachings of the aforestated previous known patents, it can be noted that, according to the present invention, the ABI 007 is used to obtain drugs the use of which enables patients to be administered with doses of Paclitaxel very much higher and with infusion durations very much shorter than is possible with the known method of intravenous administration, with favourable results (response percentage extremely high and surprising), observing very low toxicity in all cases.
More specifically, the intra-arterial administrations of the drug of the invention can be spaced apart by 3-4 weeks, with a therapeutically very favourable result, i.e. a treatment response percentage which is higher than 71% (compared with the 40°~o achieved with the traditional treatment with Paclitaxel, for example in treating head and neck cancer).
More particularly, the drug of the present invention can be used with surprising results for treating a patient afflicted with a tumor sensitive to Paclitaxel, this drug being inject;~ble directly into the artery feeding the territory associated with the tumor, taking care to use a quantity of drug containing between 190 and 500 mg of ABI 007 and that the injection in completed over a duration of about 25-60 minutes. From 2 to 5 similar intra-arterial injections are then repeated at a distance c~f 3-5 weeks one from another.
Tumors which have proved responsive to the described treatment are the squamocellular carcinomas, including certain tumors of the lung, head and neck, uterus and anal canal.
USE OF PACLTTAXEL STABILIZED WITH AhBUMIN FOR PR»PARIN(~ A
DRUG FOR THE TRI~ATl'4~1~IT Ulr' SOLID TUMORS AND THE DRUG
OBTAINED Z'IiEREBY
The invention rclat~~s~ to a drug for the treatment of Paclitaxel, and the use of albumin micropart~:cles incorporatirlg~ Paclitaxel (and lutown by the name of ADI 007) in the prcpttration of this drug.
Paclitaxel is a sttbstanr_e well known in the literature, with important clinical activity on a large number of tumors, such as ovary, Iung, head and t 0 neck, bladder and breast tumors.
Paclitaxel is insoluble in water. Irt order to render it soluble and suitable for intravenous ad~m.fnistration, it has been mixed with a surfactant (such as isolyethoxylatcd castor oil, lmoan~ by the registered name "CLCr.11up11u1 EL") and with about 50% of ranhydrous alcohol USP, ae vehicles for the 5 ParlitaxPl: thi4 mixture was patented by tiristoi-Myers Squibb and tg known by Llle, 1'C~,l'.fLClCl1 Liaiut "Taxol" to which ccfcrcnce will be tuadc hereiliaft~r, for oimplieity. The pre: once of the Surfactant and the anhydrous alcohol has CPT1f117S drawhar:kq, g»c:h as strong hypersensitivity, in addition to other side effects.
20 fn tiny ever~t,. Taxol is admixiiatered, and can be administered, only by isltravenous injection, with carry Ir_.zt,gthy admtnxgtra.tinn timrc tt~
Qxt attem.rt to minimize the toxic effects of ithe product.
To overoonne the aforesaid drawbar.L~s, the said Bristol-Myers Squibb has patented (European Parent Arrli~atinns FP..A-()Sii4()()l, H;P-A-()7lialili5, W EP-A-0783886 and United SldlCS Pr~lCIlls US 5641803 a.cld U3 5670537) ovrnpositiona also containing, in addition to Texol, other oub3tEtrtce3 or medicaments able to impedC SG:r1011S a~.Rj~h3rlR~xi~ rPa~tiflnC.
According LO the laiown arl.. its drsc,-ribcd W tile d!'urcad.iQ pGtLC~lts, from l;ib to 1'75 trig of Taxol per m2 of the patient's body surface are 30 adrninistercd intravenously to petticnt3 3ubjeeted to therapy, each adsxximistration being effected very slowly, over a dttratiori of Ahntlt 3 hnmrw it is essential always to use the aforementioned medicaments.
U3 5439686, US 5498421 and US 55609$3 deocribe albumin_ microparticles incorporating th~P Pa~litax~:l: thPSp particles are internationally identified by the symbols ABI OC17, this denomination being used hereinafter for simplicity whenever reference is made to these microparticles.
ABI 007 is in practice a formulation of Paclitaxel stabilized by human albumin USP, which care be dispersed in physiological solution which is directly injectable, being free of 'toxic emulsifiers.
It has been surprisingly found that ABI 700 can be used to prepare drugs in which the ABI 007 is present as a dispersion in physiological solutions at a concentration between 2 rng and 8 mg per ml of these solutions, and that this drug can be injected directly into those arteries which feed the terntory associated with a tumor sensitive to Paclitaxel, with administrations effected over durations much shorter than are possible in the known art, and repeated just a few times.
Compared with the teachings of the aforestated previous known patents, it can be noted that, according to the present invention, the ABI 007 is used to obtain drugs the use of which enables patients to be administered with doses of Paclitaxel very much higher and with infusion durations very much shorter than is possible with the known method of intravenous administration, with favourable results (response percentage extremely high and surprising), observing very low toxicity in all cases.
More specifically, the intra-arterial administrations of the drug of the invention can be spaced apart by 3-4 weeks, with a therapeutically very favourable result, i.e. a treatment response percentage which is higher than 71% (compared with the 40°~o achieved with the traditional treatment with Paclitaxel, for example in treating head and neck cancer).
More particularly, the drug of the present invention can be used with surprising results for treating a patient afflicted with a tumor sensitive to Paclitaxel, this drug being inject;~ble directly into the artery feeding the territory associated with the tumor, taking care to use a quantity of drug containing between 190 and 500 mg of ABI 007 and that the injection in completed over a duration of about 25-60 minutes. From 2 to 5 similar intra-arterial injections are then repeated at a distance c~f 3-5 weeks one from another.
Tumors which have proved responsive to the described treatment are the squamocellular carcinomas, including certain tumors of the lung, head and neck, uterus and anal canal.
From trials carried out it has been found that, preferably, the drug quantity used for intra-arterial therapy of tumors contains from 200 to 300 mg of ABI 007 per m2 of the patient's body surface for each administration, and that the administration of each individual dose of the dispersion is effected over about 30 minutes.
Some examples relating to the treatment of tumors of different types and locations are described to clarify the understanding and the characteristics of the present invention.
z~v w w~r~or z~ ~
A female patient (PR), S7 years of age, afflicted with pelvic recurrence of carcinoma of the anal canal, already previously treated by chemotherapy, radiotherapy and surgery and judged inoperable, is treated with four separate successive intra-arterial injections (at a distance of 4 weeks one from the other) into the internal iliac arteries, of dispersions of ABI 007 in physiological solution (Paclitaxel in microparticles of albumin) at doses of 220, 230, 250 and 275 mg per m2 of body surface respectively.
The injected dispersions have a concentration of 6 mg of ABI 007 per ml of their solution.
The reduction in 'the tumor was followed by computerized tomography. Having observed an important tumor reduction and assuming that virtually complete regression of the mass had been achieved, a surgical intervention was performed and. demonstrated the absence of the histological tumor.
To a female patient (~~N), 64 years of age, afflicted with voluminous neoplasia of the left half tongue, not previously subjected to any form of treatment, ABI 007 is administ~°red in 4 successive cycles, at a dose of 210, 230, 200 and 200 mg/m2 respectively, at a concentration of 4 mg/ml into the left lingual artery.
Response to the treatment was followed by clinical examination and magnetic resonance because of the presence of fixed dental prostheses.
Having observed important tumor regression, evaluated at 90% one month after the end of treatment, surgical intervention was proposed, and demonstrated histological absence of the tumor.
Some examples relating to the treatment of tumors of different types and locations are described to clarify the understanding and the characteristics of the present invention.
z~v w w~r~or z~ ~
A female patient (PR), S7 years of age, afflicted with pelvic recurrence of carcinoma of the anal canal, already previously treated by chemotherapy, radiotherapy and surgery and judged inoperable, is treated with four separate successive intra-arterial injections (at a distance of 4 weeks one from the other) into the internal iliac arteries, of dispersions of ABI 007 in physiological solution (Paclitaxel in microparticles of albumin) at doses of 220, 230, 250 and 275 mg per m2 of body surface respectively.
The injected dispersions have a concentration of 6 mg of ABI 007 per ml of their solution.
The reduction in 'the tumor was followed by computerized tomography. Having observed an important tumor reduction and assuming that virtually complete regression of the mass had been achieved, a surgical intervention was performed and. demonstrated the absence of the histological tumor.
To a female patient (~~N), 64 years of age, afflicted with voluminous neoplasia of the left half tongue, not previously subjected to any form of treatment, ABI 007 is administ~°red in 4 successive cycles, at a dose of 210, 230, 200 and 200 mg/m2 respectively, at a concentration of 4 mg/ml into the left lingual artery.
Response to the treatment was followed by clinical examination and magnetic resonance because of the presence of fixed dental prostheses.
Having observed important tumor regression, evaluated at 90% one month after the end of treatment, surgical intervention was proposed, and demonstrated histological absence of the tumor.
Ti'.Y 0 MDT Ti' Q
To a male patient (BP), 61 years of age, afflicted with carcinoma of the right hypopharynx, with metastasis at a right laterocervical lymph node not subjected to any previous treatment, ABI 007 is administered into the external carotid artery for 3 cycles, spaced apart by 4 weeks, at a dose of 240 mg/m2 and at a concentration of 3 mg; ml. Having observed the therapeutic response by computerized tomography and clinical examination, multiple depth biopsies were performed in the hypopharynx, in the site previously occupied by the tumor, and demonstrated histological absence of neoplasia.
The lymphonodal metastasis had also decreased by more than 80%
in dimensions and was removed by surgical intervention, with tumor presence at this level.
Ti'YAMDT.Ti' d To a female patient (EP), 37 years of age, afflicted with recurrence of carcinoma of the anal canal, previously treated by radio- chemotherapy, ABI
007 was administered into the internal iliac arteries for 4 cycles spaced apart by 4 weeks, at a dose of 250 mg,/m2 per cycle, at a concentration of 7 mg/ml.
Having observed t:he therapeutic response by gynecological examination and computerized tomography, a new surgical intervention. was proposed and demonstrated the histological absence of tumor.
Ti'Y A MDT .Ti' ~.
To a male patient (GCS, 59 years of age, afflicted with recurrence of carcinoma of the anal canal, previously treated by radio-chemotherapy, ABI
007 was administered into the internal iliac arteries at a dose of 200, 240 and 260 mg/m2 respectively, at a concentration of 7.5 mg/ml.
Having observed the response by clinical examination and transrectal echoendosonograph,y, a surgical intervention was proposed and demonstrated the histological absence of tumor.
To a male patient (BP), 61 years of age, afflicted with carcinoma of the right hypopharynx, with metastasis at a right laterocervical lymph node not subjected to any previous treatment, ABI 007 is administered into the external carotid artery for 3 cycles, spaced apart by 4 weeks, at a dose of 240 mg/m2 and at a concentration of 3 mg; ml. Having observed the therapeutic response by computerized tomography and clinical examination, multiple depth biopsies were performed in the hypopharynx, in the site previously occupied by the tumor, and demonstrated histological absence of neoplasia.
The lymphonodal metastasis had also decreased by more than 80%
in dimensions and was removed by surgical intervention, with tumor presence at this level.
Ti'YAMDT.Ti' d To a female patient (EP), 37 years of age, afflicted with recurrence of carcinoma of the anal canal, previously treated by radio- chemotherapy, ABI
007 was administered into the internal iliac arteries for 4 cycles spaced apart by 4 weeks, at a dose of 250 mg,/m2 per cycle, at a concentration of 7 mg/ml.
Having observed t:he therapeutic response by gynecological examination and computerized tomography, a new surgical intervention. was proposed and demonstrated the histological absence of tumor.
Ti'Y A MDT .Ti' ~.
To a male patient (GCS, 59 years of age, afflicted with recurrence of carcinoma of the anal canal, previously treated by radio-chemotherapy, ABI
007 was administered into the internal iliac arteries at a dose of 200, 240 and 260 mg/m2 respectively, at a concentration of 7.5 mg/ml.
Having observed the response by clinical examination and transrectal echoendosonograph,y, a surgical intervention was proposed and demonstrated the histological absence of tumor.
Claims (4)
1. Use of microparticles of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors sensitive to Paclitaxel, in particular squamocellular carcinomas, the drug comprising a dispersion of said microparticles in a physiological solution in which the microparticles are present at a concentration between 2 and 8 mg/ml of this solution.
2. Use of microparticles as claimed in claim 1, characterised in that the concentration of said microparticles in their dispersion is between 3 and 7.5 mg/ml of the physiological solution.
3. A drug for the treatment of solid tumors sensitive to Paclitaxel, characterised by comprising a dispersion of microparticles of Paclitaxel stabilized with albumin in a physiological solution in which the concentration of the microparticles is between 2 and 8 mg/ml of said solution.
4. A drug as claimed in claim 3, characterised in that in said dispersion the concentration of the microparticles is between 3 and 7.5 mg/ml of the solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2000A001107 | 2000-05-18 | ||
| IT2000MI001107A ITMI20001107A1 (en) | 2000-05-18 | 2000-05-18 | METHOD FOR TREATMENT OF SOLIC TUMORS BY INCORPORATING PACLITAXEL MICROPARTICLES OF ALBUMIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2345482A1 true CA2345482A1 (en) | 2001-11-18 |
Family
ID=11445079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002345482A Abandoned CA2345482A1 (en) | 2000-05-18 | 2001-04-27 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6652884B2 (en) |
| EP (1) | EP1155692B1 (en) |
| JP (1) | JP2001354559A (en) |
| KR (2) | KR20010105248A (en) |
| CN (1) | CN1198609C (en) |
| AT (1) | ATE267594T1 (en) |
| AU (1) | AU781517B2 (en) |
| BR (1) | BR0102040A (en) |
| CA (1) | CA2345482A1 (en) |
| DE (1) | DE60103453T2 (en) |
| DK (1) | DK1155692T3 (en) |
| ES (1) | ES2221874T3 (en) |
| HK (1) | HK1040368A1 (en) |
| HU (1) | HU229909B1 (en) |
| IL (1) | IL142674A0 (en) |
| IT (1) | ITMI20001107A1 (en) |
| MX (1) | MXPA01004980A (en) |
| NO (1) | NO330511B1 (en) |
| NZ (1) | NZ511201A (en) |
| PT (1) | PT1155692E (en) |
| RU (1) | RU2270003C2 (en) |
| TR (1) | TR200101353A3 (en) |
| ZA (1) | ZA200103755B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| ITMI20020680A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
| ITMI20020681A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | PROCEDURE FOR THE PRODUCTION OF PACLITAXEL AND ALBUMINA NANOPARTICLES |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| CN1925874B (en) * | 2002-12-09 | 2014-12-17 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivery of pharmacological agents |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX339142B (en) * | 2005-02-18 | 2016-05-13 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy. |
| KR101457834B1 (en) | 2005-08-31 | 2014-11-05 | 아브락시스 바이오사이언스, 엘엘씨 | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| TWI429452B (en) | 2005-08-31 | 2014-03-11 | Abraxis Bioscience Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| JP2009512682A (en) * | 2005-10-21 | 2009-03-26 | パナセア バイオテック リミテッド | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20150002886A (en) | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| PL2155188T3 (en) | 2007-06-01 | 2014-03-31 | Abraxis Bioscience Llc | Methods and compositions for treating recurrent cancer |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| KR101090505B1 (en) * | 2008-12-30 | 2011-12-06 | 최은아 | Composition comprising egg white-chalcanthite for preventing or treating cancer |
| MY175260A (en) | 2009-04-15 | 2020-06-17 | Abraxis Bioscience Llc | Prion free nanoparticle compositions and methods of making thereof |
| MX359413B (en) | 2010-03-26 | 2018-09-27 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma. |
| CA3087813A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ604031A (en) | 2010-06-04 | 2015-05-29 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| CN109288789A (en) | 2011-04-28 | 2019-02-01 | 阿布拉科斯生物科学有限公司 | The intravascular delivering and its application of Nanoparticulate compositions |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| MX370662B (en) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Methods of treating lung cancer. |
| EP2968253A4 (en) * | 2013-03-13 | 2016-11-02 | Abraxis Bioscience Llc | Methods of treatment of pediatric solid tumor |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| PL3313401T3 (en) | 2015-06-29 | 2022-02-07 | Abraxis Bioscience, Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| CN109906088A (en) * | 2016-08-26 | 2019-06-18 | 奥野哲治 | Microvascular blood flow reduces agent and its application |
| TWI660728B (en) | 2018-02-09 | 2019-06-01 | 國立交通大學 | Quinazolinamine derivatives and pharmaceutical compositions and uses thereof |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69433723T3 (en) | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| KR100789008B1 (en) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | Novel Formulations of Pharmacological Agents |
| EP1100494A1 (en) | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin |
-
2000
- 2000-05-18 IT IT2000MI001107A patent/ITMI20001107A1/en unknown
-
2001
- 2001-04-17 US US09/835,384 patent/US6652884B2/en not_active Expired - Lifetime
- 2001-04-18 IL IL14267401A patent/IL142674A0/en active IP Right Grant
- 2001-04-19 NZ NZ511201A patent/NZ511201A/en not_active IP Right Cessation
- 2001-04-20 AU AU38765/01A patent/AU781517B2/en not_active Expired
- 2001-04-24 JP JP2001126061A patent/JP2001354559A/en active Pending
- 2001-04-27 PT PT01110509T patent/PT1155692E/en unknown
- 2001-04-27 DE DE60103453T patent/DE60103453T2/en not_active Expired - Lifetime
- 2001-04-27 CA CA002345482A patent/CA2345482A1/en not_active Abandoned
- 2001-04-27 DK DK01110509T patent/DK1155692T3/en active
- 2001-04-27 ES ES01110509T patent/ES2221874T3/en not_active Expired - Lifetime
- 2001-04-27 AT AT01110509T patent/ATE267594T1/en active
- 2001-04-27 EP EP01110509A patent/EP1155692B1/en not_active Expired - Lifetime
- 2001-05-09 ZA ZA200103755A patent/ZA200103755B/en unknown
- 2001-05-15 TR TR2001/01353A patent/TR200101353A3/en unknown
- 2001-05-16 NO NO20012409A patent/NO330511B1/en not_active IP Right Cessation
- 2001-05-17 KR KR1020010026970A patent/KR20010105248A/en not_active Application Discontinuation
- 2001-05-17 MX MXPA01004980A patent/MXPA01004980A/en active IP Right Grant
- 2001-05-17 RU RU2001113688/15A patent/RU2270003C2/en active
- 2001-05-17 HU HU0102039A patent/HU229909B1/en unknown
- 2001-05-18 CN CNB011192585A patent/CN1198609C/en not_active Ceased
- 2001-05-18 BR BR0102040-4A patent/BR0102040A/en not_active Application Discontinuation
-
2002
- 2002-03-08 HK HK02101781A patent/HK1040368A1/en unknown
-
2008
- 2008-09-26 KR KR1020080094590A patent/KR20080091747A/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6652884B2 (en) | Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel | |
| ES2243940T3 (en) | LOCAL CONTROLLED RELEASE OF A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF SOLID TUMORS. | |
| CN1338932A (en) | Use of lipoic acid combination with ascorbic acid in the treatment of cancer | |
| ES2738512T3 (en) | Pharmaceutical formulation to treat pancreatic cancer | |
| Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
| JP2011506467A (en) | Method of treatment of melanoma with alpha thymosin peptide combined with antineoplastic heat shock apoptosis activator (HSAA) | |
| JP2004517961A (en) | Cancer treatment | |
| US7608612B2 (en) | Radiosensitizer formulations and methods for use | |
| Yeom et al. | The application of electrochemotherapy in three dogs with inoperable cancers | |
| EP0858341B1 (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
| KR101221640B1 (en) | Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms | |
| McElwain | Radiotherapy and Chemotherapy for Colorectal Cancer [Abridged] Chemotherapy in Colorectal Cancer | |
| JPH11514995A (en) | Combination of temozolomide and α-IFN for treatment of advanced cancer | |
| Raymond et al. | Protracted Continuous Infusion of 5-Fluorouracil in Combination with Doxorubicin, Vincristine, and Oral Cyclophospharnide in Advanced Breast Cancer | |
| Shaha et al. | Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation | |
| Hoffman et al. | EPCT-01. Pediatric Brain Tumor Consortium (PBTC)-055: A phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or Neurofibromatosis type-1 (NF1)-associated pediatric gliomas | |
| Kaufman | Treatment of carcinoma of the bladder with combined radiotherapy, chemotherapy, and surgery | |
| RU2207868C1 (en) | Agent for treatment of benign tumor | |
| RU2065303C1 (en) | Method for treating oncologic patients | |
| JP2002537334A (en) | Synergistic antitumor composition | |
| CN114557988A (en) | Application of benzethonium chloride in preparation of medicine for inhibiting colorectal cancer metastasis | |
| JPH04505757A (en) | Local chemotherapy with 4-hydroperoxycyclophosphamide | |
| INTRA-ARTERIAL | STUDIES ON THE BLOOD SUPPLY OF TUMORS IN MAN. II. INTRA-ARTERIAL NITROGEN MUSTARD THERAPY OF CU-TANEOUS LESIONS¹ 12 | |
| OA17078A (en) | New pediatric uses of cabazitaxel. | |
| JP2006518355A (en) | Combination therapy including indolopyrrolocarbazole derivatives and other antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |